114results about "Immunoglobulins against blood group antigens" patented technology

Methods for obtaining a protein by culture of hybridoma cells, wherein said protein is an immunoglobulin, are disclosed. The methods involve culturing animal hybridoma cells in continuous presence of an alkanoic acid or salt thereof, which enhances protein production, wherein said alkanoic acid or salt thereof is present at 2 concentration range of 0.1 mM to 200 mM.

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP)

The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and / or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and / or cancer diseases.

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:a) It specifically binds to human platelet membrane glycoprotein VI (GPVI);b) The function to activate a platelet and / or the function to induce a thrombocytopenia in vivo are low; andc) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and / or FcγRIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.

The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V / F heterozygote polymorphism.

The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immonoglobulin products.

The present invention comprises a method of purifying GPVI, GPVI peptides, cDNA and protein sequence, and methods for using GPVI and antibodies directed against GPVI.

The invention relates to methods of agglutinating or capturing cells comprising providing a mixture comprising a population of cells and a population of bacteriophage expressing a first antibody on the surface of the bacteriophage, the first antibody being specific for an antigen-bearing moiety expressed by at least a portion of the cells in the cell population, wherein the first antibody binds to the portion of the cells causing the bacteriophage to also bind to the portion of the cells, adding to the mixture a second antibody specific for the bacteriophage, wherein binding of the second antibody to bacteriophage bound to the portion of the cells causes the portion of the cells to agglutinate or be captured.

The present invention relates to a method for the production and the selection of human or chimaeric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB / CD32).

Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

The invention relates to the technical field of biology, and particularly discloses a canine single-chain antibody, and a construction method and application thereof. By designing the canine antibody variable region degenerate primers, the canine heavy chain variable region VH and light chain variable region VL genes are successfully amplified. On such basis, a bacteriophage display technique is utilized to successfully construct the canine single-chain antibody scFv library. The scFv single-chain antibody library has diversity and enough storage capacity. A Dot-ELISA method is utilized to screen 3 single chain antibodies capable of being combined with the canine DEA 1.1 blood group antigen from the scFv single-chain antibody library by using the canine DEA 1.1 blood group antigen, wherein Clone 16 has stronger combination characteristic. A pET-32a-Clone16 recombinant protein is constructed according to the Clone 16 gene to perform prokaryotic expression, and the purified antibody has combination activity. The canine single-chain antibody lays solid foundation for preparing canine DEA 1.1 blood grouping reagents.

The present invention relates to a composition comprising two or more sets of target-specific recombinant polyclonal antibodies, each set being capable of binding to a distinct target, wherein said distinct targets are related to diseases, which may be treated or prevented by the use of antibodies, and wherein said composition is essentially free from immunoglobulin molecules that do not bind to one of said distinct targets. Further the application describes pharmaceutical and diagnostic compositions comprising said composition and use in prevention, treatment and / or amelioration of one or more diseases.

The present invention is directed to a sialylated isolated antibody specific for an antigen selected from autoimmune antigens, allergens, MHC molecules or Rhesus factor D antigen, comprising an Fc-portion of IgG type, and exhibiting a sialic acid residue at the Fc-portion for use in treatment and / or prophylaxis of autoimmune disease, allergy, transplant rejection or Rhesus factor D reactivity and to methods of producing such an antibody.

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and / or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg / ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.

Anti-RhD monoclonal antibodies and methods for the production thereof.

Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

Methods for producing immunoglobulins and in particular anti-D immunoglobulin substantially free of virus and product resulting therefrom. Specifically provided are methods for nanofiltration of the anti-D immunoglobulin in high ionic strength buffer and with excipient such as polysorbate 80. Additional steps include diafiltration to concentrate the anti-D protein and reduce the concentration of excipient present.

The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.